OmniAb, Inc. (OABIW) income statement

OABIWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as OABI

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 10/309% above fair value

$0.41−0.01 (-2.38%)

Close on Oct 30, 2026Market cap $742.95MP/E –Yield –

OmniAb, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	Q3 2026 2026-09-30	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30
Revenue	3.99	13	14	8.38	2.24	3.90	4.15	11	4.17	7.61	3.80	4.82	5.48	6.95	17	35	6.91	7.20	9.62	–	–
Research & Development	9.55	9.59	9.64	14	10	11	13	13	13	14	15	15	14	14	14	13	13	11	11	–	–
General & Administrative	7.24	6.65	6.62	6.84	6.78	7.68	7.92	7.36	7.08	7.97	8.34	7.87	8.51	8.74	8.20	10	5.58	5.00	4.11	–	–
Operating Expenses	20	20	22	24	20	20	23	27	24	24	26	26	26	26	25	26	22	20	18	–	–
Operating Income	-16	-6.64	-7.83	-16	-18	-16	-19	-16	-20	-16	-23	-21	-20	-19	-8.45	9.05	-15	-13	-8.22	-0.17	0.00
Interest & Investment Income	0.52	0.43	0.49	1.23	0.46	0.44	0.54	0.66	0.69	0.79	0.98	1.18	1.27	1.29	1.32	0.59	0	0	0	–	–
Other Non-Operating Income	0.51	0.43	0.56	1.22	0.45	0.46	0.54	0.66	0.68	0.78	0.98	1.18	1.27	1.28	1.32	0.59	0	0	0	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.09	0.30	–	–	–
Pretax Income	-16	-6.21	-7.27	-15	-18	-16	-18	-15	-19	-16	-22	-20	-19	-18	-7.13	9.64	-15	-13	-8.22	–	–
Income Tax Expense	-0.13	-0.35	0.44	-0.37	-1.16	0.12	-0.11	-2.16	-2.71	-1.90	-2.62	-5.98	-3.30	-3.44	-1.03	2.82	-2.31	-2.29	-1.94	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.47	1.62	4.36	–	–
Net Income	-16	-5.86	-7.71	-14	-17	-16	-18	-13	-16	-14	-19	-14	-16	-15	-6.10	6.82	-13	-10	-6.28	-0.17	0.00
EPS (Basic)(per share)	-0.12	-0.05	-0.06	-0.11	-0.14	-0.15	-0.17	-0.12	-0.16	-0.13	-0.19	-0.14	-0.16	-0.15	-0.06	0.07	-0.15	-0.12	-0.08	-0.01	0.00
EPS (Diluted)(per share)	-0.12	-0.05	-0.06	-0.11	-0.14	-0.15	-0.17	-0.12	-0.16	-0.13	-0.19	-0.14	-0.16	-0.15	-0.06	0.07	-0.15	-0.12	-0.08	-0.01	0.00
Shares Outstanding (Basic, Weighted)(shares)	129	129	128	128	115	106	106	105	102	101	101	100	100	99	99	93	83	83	83	18	5.00
Shares Outstanding (Diluted, Weighted)(shares)	129	129	128	128	115	106	106	105	102	101	101	100	100	99	99	93	83	83	83	18	5.00
EBITDA	–	–	–	-8.06	-13	-12	-14	-8.27	-15	-10	-18	-16	-15	-15	-3.59	14	-10	-8.08	-3.79	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -115.9%
Net margin: -108.1%
Return on equity, FY2025: -23.4%

Financial strength

Current ratio: 4.21
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 135.8%

Valuation

P/E ratio: –
Price to sales: 18.48
Price to book: 2.98
Dividend yield: –